Skip to main content
SpringerLink
Log in

Infliximab and Golimumab

  • Chapter
  • First Online:
Advances in Psoriasis

  • 1200 Accesses

Abstract

Psoriasis and psoriatic arthritis are common chronic inflammatory disorders with substantial physical, financial and psychosocial burdens for patients. Biologic therapy for these conditions has been a major improvement in the therapeutic armamentarium. These drugs can maintain control of the disease, restore physical function and significantly improve the quality of life. This chapter provides a comprehensive review of the safety and efficacy of two of the monoclonal antibody tumor necrosis factor alpha (TNFα) blocking drugs. Infliximab was the first such agent approved for use in the United States in 1998. Golimumab is one of the more recent additions to this family of drugs. There has now been over 15 years of clinical experience with TNFα inhibitors. This experience has allowed physicians to utilize these agents in a manner to maximize efficacy while decreasing the risks of the potential side effect. We will summarize the published data and experience with these two specific agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther. 2011;13 Suppl 1:S2.

    PubMed Central  PubMed  Google Scholar 

  3. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–33.

    Article  CAS  PubMed  Google Scholar 

  4. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13 Suppl 1:S5.

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg. 2004;8:77–89.

    PubMed  Google Scholar 

  6. Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008;2:115–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003;7:382–6.

    Article  PubMed  Google Scholar 

  8. Services U S D o H a H. FDA Approved Drug Products, Remicade. In. 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.

  9. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm. 2011;68:795–806.

    Article  CAS  PubMed  Google Scholar 

  10. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–26.

    Article  CAS  PubMed  Google Scholar 

  11. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003;48:2155–62.

    Article  CAS  PubMed  Google Scholar 

  12. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160:810–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.

    Article  CAS  PubMed  Google Scholar 

  14. Services U S D o H a H. FDA Approved Drug Products, Simponi. In. 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.

  15. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79.

    Article  CAS  PubMed  Google Scholar 

  16. Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam. 2012;2012:819467.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.

    Article  CAS  PubMed  Google Scholar 

  18. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577–87.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744–8.

    Article  CAS  PubMed  Google Scholar 

  20. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829–30.

    Article  CAS  PubMed  Google Scholar 

  21. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7.

    Article  CAS  PubMed  Google Scholar 

  22. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–42.

    Article  PubMed  Google Scholar 

  23. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–74.

    Article  CAS  PubMed  Google Scholar 

  24. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1–15.

    Article  Google Scholar 

  25. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–36.

    Article  CAS  PubMed  Google Scholar 

  26. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498–505.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15:i–xxi, 1–329.

    CAS  PubMed  Google Scholar 

  29. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165:1109–17.

    Article  CAS  PubMed  Google Scholar 

  30. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25:1007–11.

    Article  CAS  PubMed  Google Scholar 

  31. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443–6.

    Article  PubMed  Google Scholar 

  32. Reich K, Gottlieb AB, Kimball A, Li S. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trials. J Am Acad Dermatol. 2006;54:AB215. Abstract P2871.

    Google Scholar 

  33. Warren RB, Brown BC, Carmichael AJ, Griffiths CE. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol. 2009;34:415–6.

    Article  CAS  PubMed  Google Scholar 

  34. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg. 2005;24:37–45.

    Article  CAS  PubMed  Google Scholar 

  35. Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat. 2011;22:276–84.

    Article  CAS  PubMed  Google Scholar 

  36. Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol. 2008;47:514–8.

    Article  PubMed  Google Scholar 

  37. Baranauskaite A, Raffayova H, Kungurov N, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71(4):541–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

    Article  CAS  PubMed  Google Scholar 

  39. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645–60.

    Article  CAS  PubMed  Google Scholar 

  40. Adisen E, Aral A, Aybay C, Gurer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol. 2010;37:708–13.

    Article  CAS  PubMed  Google Scholar 

  41. Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012;67(4):642–50.

    Article  CAS  PubMed  Google Scholar 

  42. Haitz KA, Kalb RE. Infliximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol. 2007;57:120–5.

    Article  PubMed  Google Scholar 

  43. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.

    Article  CAS  PubMed  Google Scholar 

  44. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.

    Article  PubMed  Google Scholar 

  45. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1–70.

    Article  PubMed  Google Scholar 

  46. Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents. J Drugs Dermatol. 2009;8:147–54.

    PubMed  Google Scholar 

  47. Eisendle K, Fritsch P. Fatal fulminant legionnaires’ disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy. Br J Dermatol. 2005;152:585–6.

    Article  CAS  PubMed  Google Scholar 

  48. Vamvouris T, Hadi S. A review of the treatment of psoriasis with infliximab. Rev Recent Clin Trials. 2006;1:201–5.

    Article  CAS  PubMed  Google Scholar 

  49. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin. 2005;23:259–300.

    Article  PubMed  CAS  Google Scholar 

  50. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis. 2005;64 Suppl 2:ii78–82.

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Bartke U, Venten I, Kreuter A, Gubbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol. 2004;150:784–6.

    Article  CAS  PubMed  Google Scholar 

  52. Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol. 2010;24:307–11.

    PubMed Central  PubMed  Google Scholar 

  53. Dixon W, Felson DT. Is anti-TNF therapy safer than previously thought? JAMA. 2011;306:2380–1.

    Article  CAS  PubMed  Google Scholar 

  54. Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther. 2011;34:181–7.

    Article  CAS  PubMed  Google Scholar 

  55. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250–6.

    PubMed  Google Scholar 

  56. Kleyn CE, Griffiths CE. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther. 2006;6:797–805.

    Article  CAS  PubMed  Google Scholar 

  57. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527–36.

    Article  CAS  PubMed  Google Scholar 

  58. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49:S112–7.

    Article  PubMed  Google Scholar 

  59. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124:917–24.

    Article  CAS  PubMed  Google Scholar 

  60. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:1647–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31:1912–7.

    CAS  PubMed  Google Scholar 

  62. Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782–9.

    Article  CAS  PubMed  Google Scholar 

  64. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75–84.

    Article  CAS  PubMed  Google Scholar 

  65. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

    Article  CAS  PubMed  Google Scholar 

  66. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–45.

    Article  CAS  PubMed  Google Scholar 

  67. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  68. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159:1217–28.

    Article  CAS  PubMed  Google Scholar 

  69. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327–46.

    Article  CAS  PubMed  Google Scholar 

  70. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403–12.

    Article  CAS  PubMed  Google Scholar 

  71. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003;42:617–21.

    Article  CAS  Google Scholar 

  72. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–9.

    Article  CAS  PubMed  Google Scholar 

  73. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807–16.

    Article  CAS  PubMed  Google Scholar 

  74. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352:351–61.

    Article  Google Scholar 

  76. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639–41.

    Article  PubMed  Google Scholar 

  77. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64 Suppl 2:ii87–90; discussion ii91–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261–5.

    Article  CAS  PubMed  Google Scholar 

  79. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819–36.

    Article  CAS  PubMed  Google Scholar 

  80. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601–11.

    Article  CAS  PubMed  Google Scholar 

  82. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160:8–15.

    Article  CAS  PubMed  Google Scholar 

  83. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009;161:797–800.

    Article  CAS  PubMed  Google Scholar 

  84. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650–3.

    Google Scholar 

  85. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28:787–91.

    Article  CAS  PubMed  Google Scholar 

  86. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366–71.

    Article  CAS  PubMed  Google Scholar 

  87. Paradisi A, Caldarola G, Capizzi R, et al. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol. 2010;62:1067–9.

    Article  PubMed  Google Scholar 

  88. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004;51:580–4.

    Article  PubMed  Google Scholar 

  89. Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257–64.

    Article  CAS  PubMed  Google Scholar 

  90. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306:2331–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg. 2011;15:397–403.

    Article  PubMed  Google Scholar 

  92. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956–62; discussion 962–3.

    Article  PubMed  Google Scholar 

  93. Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202–7; discussion 1207–10.

    Article  CAS  PubMed  Google Scholar 

  94. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J GastrointestSurg. 2008;12:1730–6; discussion 1736–7.

    Article  Google Scholar 

  95. Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009;15:1062–70.

    Article  CAS  PubMed  Google Scholar 

  96. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68:1177–83.

    Article  CAS  PubMed  Google Scholar 

  97. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53.

    Article  CAS  PubMed  Google Scholar 

  98. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648–53.

    Article  CAS  PubMed  Google Scholar 

  99. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1414–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  100. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  101. Leonardi CL, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204–14.

    Article  CAS  PubMed  Google Scholar 

  102. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740–51.

    Article  CAS  PubMed  Google Scholar 

  103. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56:1433–9.

    Article  CAS  PubMed  Google Scholar 

  104. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886–95.

    Article  PubMed  Google Scholar 

  105. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther. 2009;22:418–30.

    Article  PubMed Central  PubMed  Google Scholar 

  106. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194–201.

    Article  CAS  PubMed  Google Scholar 

  107. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757–64.

    Article  CAS  PubMed  Google Scholar 

  108. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  109. Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in Behcet’s disease. Clin Exp Rheumatol. 2007;25:S65–9.

    CAS  PubMed  Google Scholar 

  110. Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine. 2009;76:333–42.

    Article  CAS  PubMed  Google Scholar 

  111. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242–51.

    Article  PubMed  Google Scholar 

  112. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716–20.

    Article  CAS  Google Scholar 

  113. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241–8.

    CAS  PubMed  Google Scholar 

  114. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010;162:780–5.

    Article  CAS  PubMed  Google Scholar 

  115. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774–81.

    Article  CAS  PubMed  Google Scholar 

  116. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  117. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.

    Article  PubMed  CAS  Google Scholar 

  118. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66:1252–4.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  119. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431–40.

    Article  PubMed  Google Scholar 

  120. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010;38:82–9.

    Article  CAS  PubMed  Google Scholar 

  121. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010;146:186–8.

    PubMed  Google Scholar 

  122. Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. Br J Dermatol. 2004;151:1272–3.

    Article  CAS  PubMed  Google Scholar 

  123. Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol Online J. 2008;14:12.

    PubMed  Google Scholar 

  124. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol. 2008;14:353–6.

    Article  PubMed  Google Scholar 

  125. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513–8.

    Article  CAS  PubMed  Google Scholar 

  126. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–8.

    Article  CAS  PubMed  Google Scholar 

  127. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486–504.

    Article  CAS  PubMed  Google Scholar 

  128. Harris MD, Richards R. First case report of adalimumab-induced psoriasis in Crohn’s disease. Am J Gastroenterol. 2009;104:792–3.

    Article  PubMed  Google Scholar 

  129. Richetta A, Mattozzi C, Carlomagno V, et al. A case of infliximab-induced psoriasis. Dermatol Online J. 2008;14:9.

    CAS  PubMed  Google Scholar 

  130. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996–1001.

    Article  CAS  PubMed  Google Scholar 

  131. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318–27.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA

    Cerrene N. Giordano MD & Robert E. Kalb MD

Authors
  1. Cerrene N. Giordano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Kalb MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cerrene N. Giordano MD .

Editor information

Editors and Affiliations

  1. St. Luke's -Roosevelt Hospital Center, New York, New York, USA

    Jeffrey M. Weinberg

  2. Department of Dermatology, Icahn School of Medicine, New York, New York, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Giordano, C.N., Kalb, R.E. (2014). Infliximab and Golimumab. In: Weinberg, J., Lebwohl, M. (eds) Advances in Psoriasis. Springer, London. https://doi.org/10.1007/978-1-4471-4432-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4432-8_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4431-1

  • Online ISBN: 978-1-4471-4432-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation